UPDATE 1-Sucampo, Takeda bowel-drug study shows mixed data

* Drug fails in one trial, succeeds in another

* To continue another follow-on trial

* Sucampo shares up 8 pct

July 21 (Reuters) - Sucampo Pharmaceuticals Inc (SCMP.O) and a unit of Japan's Takeda Pharmaceutical (4502.T) said two identical late-stage trials of their experimental drug for opioid-induced bowel dysfunction (OBD) showed mixed results, with one study meeting the main goal and the other failing.

The study named OBD0631 met the main goal of showing a statistically significant change in the frequency of spontaneous bowel movements at the eighth week of treatment when the drug, lubiprostone, was compared to a dummy drug.

However, another trial, named OBD0632, failed to achieve the same goal.

Sucampo will continue another follow-on safety study in 445 patients who would receive one 24-mcg gel capsule of lubiprostone twice a day for nine months. It expects data from this study in late 2009.

If the follow-on study is successful, Sucampo expects to submit the data to U.S. health regulators in 2010.

Sucampo shares were up 8 percent at $7.00 in trading after the bell. They closed at $6.50 Tuesday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Vinu Pilakkott)